GLAMOR-P Tablets
When Control Need Two Hands
COMPOSITION: Glimepiride IP 2 mg + Pioglitazone Hydrochloride 15 mg Tabs
- The combination is indicated in patients with type-II diabetes when diet, exercise, and the single agents do not result in adequate glycemic control.
- Diabetes is a strong, independent risk factor for cardiovascular disease, causing a 2- to 4-fold increase in cardiovascular mortality in patients with T2D.
- Type 2 diabetes mellitus is characterized by insulin resistance and progressive β cell failure; therefore, β cell secretagogues are useful for achieving sufficient glycemic control.
INDICATIONS:
- Type-II Diabetes Millitus
Description
Glimepiride
- Drug class: Sulfonylureas
- Glimepiride lowers blood glucose by stimulating pancreatic β cells to release insulin.
- Shows a significant decrease in triglycerides and an increase in high-density lipoprotein.
- Induces PPAR gamma activity, thereby improving insulin resistance.
Pioglitazone
- Drug class: Thiazolidinediones
Pioglitazone HCl
- Pioglitazone hydrochloride, a thiazolidinedione compound, is a new therapeutic agent for the treatment of type 2 diabetes that reduces insulin resistance by enhancing insulin action in skeletal muscle, liver, and adipose tissue.
- Pioglitazone HCL is a PPAR-γ agonist that increases insulin-stimulated glucose uptake in peripheral tissues.
Combination
In a study of the long-term effect of TZD, the combination was associated with significantly reduced plasma lipoprotein (a) levels, a known risk factor for cardiovascular disease, compared with the rosiglitazone combination
